Form 10-Q Akebia Therapeutics, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Akebia Therapeutics (AKBA) PT Lowered to $18 at Needham & Company
August 9, 2018 1:40 PM EDTNeedham & Company lowered its price target on Akebia Therapeutics (NASDAQ: AKBA) to $18.00 (from $20.00) while maintaining a Buy rating.
Analsyt Chad Messer notes vadadustat pivotal readouts were pushed out. "We continue to expect that INNO2VATE will be fully enrolled by YE:18; however,... More
